Each issue of Pharmaceutical Engineering® covers a wide range of topics relevant to the pharmaceutical industry, including scientific, technological, and regulatory advancements throughout the entire...
Each issue of Pharmaceutical Engineering® covers a wide range of topics relevant to the pharmaceutical industry, including scientific, technological, and regulatory advancements throughout the entire...
Krisha Patel is Co-Founder of Assurea LLC, a digital compliance consulting firm that provides IT and validation services, software assurance, and custom artificial intelligence solutions for biotech companies. With a degree in bioprocessing science and more than 12 years of experience in computer system validation and quality assurance, Patel has worked with cell and gene therapy companies,...
Massimiliano Cesarini, MEng, was named CEO of Biogenera SpA, Bologna, Italy in 2024. He began his career at Duferco Engineering in energy generation, then moved to Comecer Group, holding roles as project and product manager, and global sales manager for the pharma and advanced therapy medicinal product (ATMP) division. He eventually joined Omnia Technologies Group establishing the Omnia Life...
Niranjan S. Kulkarni, PhD, was honored with the ISPE Max Seales Yonker Member of the Year Award at the 2024 ISPE Annual Meeting & Expo in Orlando, Florida, US.
Effective containment systems in a pharmaceutical manufacturing facility are essential to protect the health of workers, the environment, and patients receiving the medications. Particles released into the facility can cause adverse side effects to facility employees, and particles released outside the facility can harm the atmosphere and nearby waterways.
The ISPE Commissioning & Qualification (C&Q) Community of Practice (CoP) conducted a survey in 2023 on the adoption of integrated C&Q, specifically on the use of paperless digital systems for planning, executing, and reporting C&Q activities. The survey revealed that 74% of respondents planned to use Digital Validation Tools (DVTs) for C&Q by 2024.